Life Extension Magazine November 2008
Detect Your Risk of Sudden Heart Attack and Stroke
By Laurie Barclay, MD
A new blood test can accurately identify atherosclerotic plaque that is vulnerable to rupture, and help to stave off fatal cardiac events. By pinpointing individuals who are in imminent danger of an ischemic (no blood flow) event, the innovative PLAC® blood test alerts physicians and patients to the urgent need to implement aggressive protective measures. As the PLAC® test becomes more widely utilized, it promises to dramatically reduce the risk of sudden heart attack and stroke.
Detecting Vulnerable Plaque
When Tim Russert succumbed to a fatal heart attack in June of this year, the world was shocked not only by the loss of an iconic TV news personality, but also by the unexpected nature of his death. Tim Russert had coronary artery disease that was supposedly controlled with medication and exercise. A stress test in late April was unremarkable. The autopsy revealed that cholesterol plaque rupturing in a coronary artery choked off the blood supply through that artery, causing Tim Russert’s fatal heart attack.1
An atherosclerotic plaque, also known as an atheroma, is a deposit of harmful fats, or lipids, on the blood vessel wall. When the plaque ruptures, globules resembling chunks of oatmeal break loose and suddenly clog a blood vessel, causing heart attack or stroke.
Cardiology experts noted the crucial difference between gradual narrowing of arteries, which had been controlled in Russert, versus the sudden, fatal blockage of a main coronary artery by ruptured atherosclerotic plaque on the vessel wall. Because about half of people who have a heart attack have no symptoms before the acute event,1 it is critical that they are recognized and treated before it is too late.
Similarly, acute, debilitating stroke, also caused in many cases by plaque rupture, often occurs without warning. Imaging tests, such as carotid ultrasound or heart computed tomography (CT), can tell us about the current anatomical state of blood vessels supplying the brain and heart, but even they cannot identify plaque that is vulnerable to rupture.2,3 In addition, CT technology involves radiation exposure, and coronary angiography requires injection of dye that may cause complications in some individuals.
In the developed world, heart disease remains the leading cause of death and disability for both men and women.4,5 While traditional risk factors such as age, gender, low-density lipoprotein (LDL), triglycerides, high-density lipoprotein (HDL), blood pressure, waist circumference, and blood sugar help predict who will develop chronic atherosclerosis, they cannot predict everyone who will suffer an acute cardiovascular event.
Fortunately, the new PLAC® test, performed on a routine blood sample, can help identify individuals who are at risk for stroke or heart attack.2
PLAC® Test Identifies Atherosclerotic Plaques Ready to Rupture
The PLAC® test measures blood levels of an enzyme called lipoprotein phospholipase A2 (Lp-PLA2). The Lp-PLA2 enzyme unleashes a chain of harmful events culminating in endothelial dysfunction, which is a pathological abnormality in the blood vessel wall that sets the stage for atherosclerosis, plaque accumulation, and rupture.6
An elevated level of Lp-PLA2 may signal that an arterial plaque is susceptible to rupture, which could cause a clot to break loose, precipitating a heart attack or stroke.
Traditional markers of cardiovascular risk such as cholesterol levels tell physicians very little about acute risk of stroke or heart attack.7 However, there is an important biochemical relationship between low-density lipoprotein (LDL) and Lp-PLA2. LDL particles are oxidized by oxygen free radicals, and these oxidized LDL particles penetrate into the intima, the innermost layer of the blood vessel wall.8
The PLAC® test measures the activity of the Lp-PLA2 enzyme associated with LDL particles when they are oxidized. David G. Harrison, MD, FACC, FAHA of Emory University School of Medicine in Atlanta, GA, notes, “if one has an elevated PLAC® test, it indicates that the person has [inflamed] atherosclerotic plaques in which LDL oxidation is occurring.”
Lp-PLA2 is made in the plaque itself and acts as a specific marker of inflammation that appears to be directly involved in forming rupture-prone atherosclerotic plaque. Patients with coronary artery disease have markedly elevated Lp-PLA2 levels, reflecting build-up of vulnerable plaque in the blood vessel wall.7,8
An autopsy study of 25 patients with sudden coronary death used antibody to Lp-PLA2 to track its presence within diseased coronary arteries. Although early plaques had very light staining for Lp-PLA2, or none at all, ruptured plaques that had caused sudden death showed intense Lp-PLA2 staining deep within the plaque.9
Similarly, patients undergoing surgery related to atherosclerosis of the carotid artery, one of the main arteries supplying the brain, had intense staining for Lp-PLA2 within macrophages—a type of white blood cell involved in plaque inflammation. Those who had carotid artery disease without symptoms had much less intense staining for Lp-PLA2.10
PLAC® Test Predicts Acute Cardiovascular Events
High levels of Lp-PLA2 predict increased rates of coronary heart disease and stroke in multiple population-based studies. Physicians from the prestigious Mayo Clinic and other experts recently reviewed more than 25 published studies of Lp-PLA2, including a compilation of 14 prospective epidemiologic studies of 20,000 patients. They concluded that Lp-PLA2 is consistently linked to higher risk of heart attack and stroke, and that this increased risk is not significantly changed when conventional risk factors for cardiovascular disease are also considered. They determined that Lp-PLA2 is unique in being highly specific for plaque inflammation, as well as being involved in causing that inflammation.11-13
The PLAC® test is as sensitive and more specific than other markers for the prediction of acute events, allowing for enhanced ability to identify people who are at increased risk for an acute ischemic event.
Lp-PLA2 has been shown to predict endothelial function in a number of studies.6,14 A striking example of this is a study showing that individuals in the highest third of Lp-PLA2 levels are more than three times as likely to have coronary endothelial dysfunction than those in the lowest third.14 In this study, Lp-PLA2 levels predicted endothelial dysfunction independently of their association with cholesterol and other cardiovascular risk factors. A review of available studies shows that individuals with high levels of Lp-PLA2 have about two to three times the risk for acute cardiovascular events, and that this risk is independent of traditional cardiovascular risk factors.2,12,13 The association of high Lp-PLA2 levels with acute cardiovascular risk holds true even in apparently healthy older adults.15
Although LDL and other lipids are not consistent predictors of stroke risk, elevated Lp-PLA2 approximately doubles stroke risk.7,16
Who Should Receive the PLAC® Test, and How Often?
Currently, the most validated role for PLAC® test is in individuals with moderate or greater risk for cardiovascular events based on traditional risk factors, in whom an elevated level would prompt more aggressive risk factor modification, such as more intensive reduction of cholesterol levels and/or blood pressure, and greater emphasis on diet and lifestyle changes. Individuals in whom traditional risks are not known, such as a patient who is adopted and in whom family history is uncertain, may also particularly benefit from the PLAC® test.
Based on the well-known and extensive Framingham study, risk of cardiovascular events can be calculated for a given patient.17 Some experts suggest that the PLAC® test be done in patients in whom the risk of having an acute event within 10 years is estimated to be 5-20%, according to a formula based on the Framingham study.
A recent expert consensus panel review for the clinical use of Lp-PLA2 testing7 recommends that the test be used in moderate and high-risk patients,12 but not as a screening test for individuals at low risk of cardiovascular disease and stroke.
The consensus panel simplified the definition of moderate risk from that based on the Framingham study, and defined it as any one or more of the following: age 65 or older, currently smoking, metabolic syndrome, fasting blood sugar over 99, or any two or more traditional risk factors for cardiovascular disease.7
In patients with metabolic syndrome, the PLAC® test is clearly more specific for prediction of risk than the C-reactive protein test, which appears to increase in response to the presence of metabolic syndrome.7
The PLAC® test should be done once each year in persons who are obese, who have high blood pressure, type 2 diabetes mellitus, high cholesterol, or a strong family history of stroke and coronary heart disease. Regular smokers also need to be tested.
In patients receiving heart transplants, Lp-PLA2 levels also predict risk of heart attack and cardiac death related to inflammation in the arteries of the transplanted heart, a condition known as cardiac allograft vasculopathy.18
PLAC® Test Helps Guide Cardiovascular Risk Management
Although Lp-PLA2 is not a primary target of therapy, the expert consensus panel7 recognizes that patients with high Lp-PLA2 have evidence of vascular inflammation and should therefore be treated more intensively with preventive therapy to lower risk of a cardiovascular event. The panel recommends that patients with high Lp-PLA2 levels be upgraded from moderate risk to high risk, or from high risk to very high risk. In these patients, a suitable goal is to lower LDL to 100 mg/dL in high-risk patients and to 70 mg/dL in very high-risk patients.7
Patients with a cluster of cardiovascular risk factors known as the metabolic syndrome, namely overweight, abnormal blood lipids, high blood sugar, and high blood pressure, may also benefit from monitoring Lp-PLA2 and from treatment strategies, such as intensified lifestyle changes and combination lipid-lowering therapy, that reduce Lp-PLA2.2,12,19
In addition to its use to gauge the intensity of lifestyle and pharmacologic interventions needed, the PLAC® test can be used serially to assess the response to these therapies. Statins for elevated cholesterol typically reduce Lp-PLA2 levels by 20-30%, and the addition of niacin or a fibrate drug in combination can achieve an additional 5-20% lowering.
In addition to statins and fibrates, orlistat and other lipid-lowering drugs also lower Lp-PLA2, allowing progress of therapy to be monitored with the PLAC® test.11,16,19,20
Blood pressure medications known as angiotensin-converting enzyme (ACE) inhibitors also lower peak phospholipase A2, and some scientists have suggested that the therapeutic efficacy of cardiovascular drugs may depend, to some degree, on their ability to lower markers of vascular inflammation such as Lp-PLA2.2,10
Omega-3 fatty acids and niacin show promise in reducing plasma Lp-PLA2.21,22 Additionally, a protein isolated from the turmeric spice (curcumin) inhibits a form of phospholipase A2 found in the animal kingdom.23